Arbutus appoints melissa v. rewolinski, phd to its board of directors

Warminster, pa., july 12, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of melissa v. rewolinski, phd, to its board of directors, effective july 12, 2023.
ABUS Ratings Summary
ABUS Quant Ranking